Emerging cystic fibrosis pathogens and the microbiome

Area of Science:

• Microbiology
• Infectious Diseases
• Pulmonary Medicine

Background:

• Cystic fibrosis (CF) respiratory infections typically involve common bacteria like Pseudomonas aeruginosa.
• Emerging pathogens unique to CF patients, including Burkholderia and Stenotrophomonas, pose significant challenges.
• Recent molecular studies reveal high prevalence of anaerobic Prevotella species and Streptococcus milleri group in CF sputum.

Purpose of the Study:

• To discuss the challenges presented by emerging CF pathogens.
• To explore the implications of a microbiome-based view of CF infection.
• To analyze the impact on clinical outcomes, diagnosis, and therapy.

Main Methods:

• Literature review and synthesis of current research on CF pathogens.
• Analysis of molecular methods used for identifying microbial diversity in CF sputum.
• Discussion of clinical data related to emerging pathogens and microbiome composition.

Main Results:

• Identification of a diverse range of typical and atypical bacterial pathogens in CF respiratory infections.
• Confirmation of anaerobic bacteria Prevotella and Streptococcus milleri group as prevalent in CF sputum.
• Recognition of the "CF microbiome" as a complex ecosystem influencing disease.

Conclusions:

• Emerging pathogens and the overall CF microbiome significantly impact clinical outcomes.
• A microbiome-centric approach is essential for advancing CF diagnosis and therapeutic strategies.
• Further research is needed to fully understand and target the complex microbial landscape in CF.